HE HELP Cango Inc. Loading... : Bullish and Bearish Analyst Opinions

The author claims Cybin (HELP) is highly undervalued relative to other psychedelic stocks and that Phase 3 data due in about a month is the catalyst for a price surge ahead of any CMPS approval. The rationale is that its deuterated psilocybin is more stable and predictable, requiring only 3-hour sessions twice a year versus Spravato's twice-weekly sessions, and that its Phase 3 trial design mirrors the CMPS trial that received FDA breakthrough designation in Phase 2. The stated catalyst is the imminent Phase 3 readout, with the implied horizon of roughly one month. No specific downside risk is stated beyond the general dependence on trial results.

The author claims Cybin (HELP) is highly undervalued relative to other psychedelic stocks and has Phase 3 data coming with a trial design modeled exactly like CMPS, which had FDA breakthrough designation for Phase 2. They argue its deuterated psilocybin is more stable and predictable, requiring only 3-hour therapy sessions twice a year versus Spravato's 2x weekly sessions, making it a superior commercial profile. The stated catalyst is the Phase 3 data readout, which the author expects to drive the stock higher before CMPS approval. Main risk implied is clinical/regulatory failure of the Phase 3 program.

Helus posts mid-stage trial data for anxiety disorder therapy $HELP #business #finance #stocks https://t.co/JMOMCkO0E9